Business
Immuneering Provides Positive Update on Phase 2a Arm Studying IMM-1-104 in Combination with Modified FOLFIRINOX for First-Line Pancreatic Cancer
- Two new partial responses (PRs) reported in Phase 2a arm studying IMM-1-104 in combination with modified FOLFIRINOX (mFFX) in first-line pancreatic cancer -
About this update from Immuneering Corporation
[{"type":"text","content":"- Two new partial responses (PRs) reported in Phase 2a arm studying IMM-1-104 in combination with modified FOLFIRINOX (mFFX) in first-line pancreatic cancer - - Overall Response Rate (ORR) of 50%; historic benchmark of 32% for FOLFIRINOX alone - - Nearly $14M in net proceeds raised in January 2025 through utilization of Company’s ATM - CAMBRIDGE, Mass., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize more effective and better tolerated therapies for cancer patients, today announced a positive update from its Phase 2a arm studying IMM-1-104 in combination with modified FOLFIRINOX (mFFX) in first-line pancreatic cancer, and provided a corporate update. “We are thrilled to report two more responses in our Phase 2a arm studying IMM-1-104 in combination with modified FOLFIRINOX in first-line pancreatic cancer,” said Ben Zeskind, Ph.D., CEO of Immuneering. “The response rates emerging from both of our Phase 2a combination arms in first-line pancreatic cancer are comparable to one another, and speak not only to IMM-1-104’s potential to drive a new standard of care in pancreatic cancer, but also its potential as a first-of-its-kind, well-tolerated MEK inhibitor that could be safely used in a variety of combinations to drive better outcomes for patients across a range of indications.” Zeskind continued: “Building on our positive January 7, 2025 data update, we strengthened our cash balance with nearly $14 million in net proceeds raised through our ATM facility. We began 2025 strong and intend to sustain that momentum throughout the year, including with a planned second quarter 2025 Phase 2a trial data update, the anticipated initiation of new combination trial arms, and planning for a pivotal trial of IMM-1-104 in combination with modified gemcitabine/nab-paclitaxel.” Data Update from Phase 2a Arm Evaluating IMM-1-104 with Modified FOLFIRINOX in First Line Pancreatic Cancer as of January 6, 2025 Source: Immuneering Corporation Since the Company’s prior update on January 7, 2025 (which used a data cutoff date of December 5, 2024), two new partial responses (PRs) have been reported.As of January 6, 2025, there were six evaluable patients in the Phase 2a arm evaluating IMM-1-104 with modified FOLFIRINOX in first-line pancreatic cancer; three pat...